Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A cluster of cancer trials
March 2019
SHARING OPTIONS:

PARIS & CAMBRIDGE, Mass.—Nanobiotix and The University of Texas MD Anderson Cancer center are expanding their business relationship in a big way, having announced a comprehensive clinical research collaboration that will initially include nine new Phase 1/2 clinical trials with NBTXR3. The trials will look at the utility of treatment with NBTXR3 in head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers. NBTXR3 is engineered to activate the immune system and destroy cancer cells when activated by radiotherapy, and the trials conducted by MD Anderson will explore the compound’s efficacy with different radiation levels. Under the terms of the agreement, Nanobiotix will make a $12-million investment, with part of the amount paid up front, part paid during development and the balance paid out in the event of FDA registration.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.